Biocept (Biocept) GF Value : $2.10 (As of May. 03, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Biocept GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-03), Biocept's share price is $0.0001. Biocept's GF Value is $2.10. Therefore, Biocept's Price-to-GF-Value for today is 0.00.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Biocept is Possible Value Trap, Think Twice.

Biocept (OTCPK:BIOCQ) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Biocept's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	0.0001	/	2.10
	=	0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocept GF Value Related Terms

Thank you for viewing the detailed overview of Biocept's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocept (Biocept) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Biocept Inc (OTCPK:BIOCQ) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

9955 Mesa Rim Road, San Diego, CA, USA, 92121

Website

https://www.biocept.com

Biocept Inc develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. In addition to its portfolio of blood-based liquid biopsy assays, Biocept has developed the CNSide cerebrospinal fluid assay that detects cancer that has metastasized to the central nervous system. Biocept's patented Target Selector technology captures and quantitatively analyzes CSF tumor cells for tumor-associated molecular markers, using technology first developed for use in blood. It is also leveraging its molecular diagnostic capabilities to offer nationwide COVID-19 RT-PCR testing to support public health efforts during this unprecedented pandemic.

Executives

Robert Walsh	officer: VP, Controller	9955 MESA RIM ROAD, SAN DIEGO CA 92121
Quyen Thi Dao-haddock	director	C/O: PRESIDIO PROPERTY TRUST, INC., 1282 PACIFIC OAKS PLACE, ESCONDIDO CA 92029
Philippe Marchand	officer: Chief Operations Officer	C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Darrell Taylor	officer: Sr. V.P., General Counsel	C/O BIOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
David F Hale	director, officer: EXECUTIVE CHAIRMAN	1042-B NORTH EL CAMINO REAL, SUITE 430, ENCINITAS CA 92024
Antonino Morales	director	C/O BICOCEPT, INC., 9955 MESA RIM ROAD, SAN DIEGO CA 92121
Linda M Rubinstein	director	25861 INDUSTRIAL BLVD, HAYWARD CA 94545
Samuel D Riccitelli	director	2850 FRONTIER DR., WARSAW IN 46582
Michael C Dugan	officer: Chief Med Off & Med. Director	2211 MICHIGAN AVE, SANTA MONICA CA 90404-3900
Dunn Cory	officer: Sr. VP Corp. Development	C/O BIOCEPT, INC., 5810 NANCY RIDGE DR., # 150, SAN DIEGO CA 92121
Edwin Hendrick	officer: SVP, Chief Commercial Officer	2010 MAIN STREET, SUITE 600, IRVINE CA 92614
Michael J Terry	officer: Sr VP Comm. Operations
Marsha Alpert Chandler	director	7863 ENTRADA ANGELICA, SAN DIEGO CA 92127
Michael W. Nall	director, officer: CEO AND PRESIDENT	4 WOODHAVEN DRIVE, LAGUNA NIGUEL CA 92677
Timothy Kennedy	officer: CFO, Sr V.P. Operations & Sec.	5810 NANCY RIDGE DRIVE, SUITE 150, SAN DIEGO CA 92121